CAY 1

Drug Profile

CAY 1

Latest Information Update: 17 Feb 2006

Price : $50

At a glance

  • Originator National Institutes of Health (USA); Southern Regional Research Center
  • Developer MycoLogics; National Institutes of Health (USA); Southern Regional Research Center
  • Class Antifungals; Saponins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Mycoses

Most Recent Events

  • 17 Feb 2006 No development reported - Preclinical for Mycoses in USA (unspecified route)
  • 16 Oct 2002 Preclinical trials in Mycoses in USA (unspecified route)
  • 18 Apr 2002 No development reported - Preclinical for Mycoses in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top